Impact of antiretroviral regimen switches on adherence

HIV Clinical Trials

Volumn 3, Issue 5, 2002, Pages 355-360

  Miller, Loren G ^a   Golin, Carol E ^a   Hays, Ron D ^a   Liu, Honghu ^a   Beck, C Keith ^a   Kaplan, Andrew H ^a   Wenger, Neil S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Adherence; Antiretroviral therapy; Compliance; HIV; Medication; Switching

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR;

ADULT; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DEVICE; DRUG DOSAGE FORM; DRUG USE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID; MAJOR CLINICAL STUDY; PALATABILITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PILL; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; STATISTICAL ANALYSIS;

EID: 0036750070     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/nnk4-gagd-5c1y-k9qt     Document Type: Article

References (24)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
2. Golin C, Kaplan A, Liu HH, et al. Patient factors associated with and self-reported reasons for nonadherence to antretroviral therpy. Presented at the 22nd annual meeting of the Society of General Internal Medicine, April 1999. J Gen Intern Med. 1999;14 (suppl 2):35.
3. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.
4. Moreno A, Perez-Elias MJ, Casado JL, et al. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice. Antivir Ther. 2000;5:243-248.
5. Giron-Gonzalez JA, Lopez-Sanchez A, Elvira JPE, Fernandez-Gutierrez C. Effect of patient adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors. Eur J Clin Microbiol Infect Dis. 2000;19:852-858.
6. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; February 1999; Chicago. Abstract 98.
7. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
8. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38-45.
9. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:841-847.
10. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221-228.
11. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239.
12. Kossovsky MP, Micheli P, Simonet ML, et al. Patients knowledge about their medication is disturbed by changes made during a hospital stay [abstract]. J Gen Intern Med. 2001;16(suppl 1):148.
13. Roberts KJ. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care STDS. 2000;14:155-168.
14. Manfredi R, Chiodo F. Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study. Int J STD AIDS. 2001;12:84-88.
15. Guardiola JM, Domingo P, Vazquez G. Switching HIV-1 protease inhibitor therapy: Which? When? And why? Arch Intern Med. 1999;159:194-195.
16. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17:1-11.
17. Abbott's liquid Ritonavir - get used to it. Newsline People AIDS Coalit N Y. 1998; September:50.
18. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
19. Kaplan A, Golin C, Beck K, et al. Adherence to protease inhibitor therapy and viral load. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; February 1999; Chicago. Abstract 96.
20. Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med. 2000;160:2491-2496.
21. Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program. Am J Manag Care. 2000;6:593-601.
22. Butcher D, Greene J, Duong P, Markson L. Virologic response associated with a change in protease inhibitor therapy. Arch Intern Med. 1999;159:194-195.
23. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385-391.
24. Hogg RS, Yip B, Chan K, O'Shaughnessy MV, Montaner JSG. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; February 2000; San Francisco. Abstract 73.